Akari Therapeutics (AKTX) Profit After Tax (2014 - 2026)

Akari Therapeutics has disclosed Profit After Tax across 9 years of filings, most recently posting -$14.5 million for Q1 2026.

• Profit After Tax for Q1 2026 came in at -$14.5 million, down 290.15% year-over-year; the trailing twelve-month figure through Mar 2026 was -$28.0 million (up 81.8% YoY), and the FY2025 annual result was -$17.3 million, up 12.6% from the prior year.
• Profit After Tax came in at -$14.5 million for Q1 2026 at Akari Therapeutics, down from -$5.3 million in the prior quarter.
• In the past five years, Profit After Tax ranged from a high of $1.0 million in Q1 2023 to a low of -$140.0 million in Q4 2024.
• The 4-year median for Profit After Tax is -$4.1 million (2023), against an average of -$15.2 million.
• Across the five-year window, Profit After Tax tumbled 3283.11% in 2024 and soared 96.22% in 2025, its largest moves.
• Akari Therapeutics' Profit After Tax stood at -$4.1 million in 2023, then sank by 3283.11% to -$140.0 million in 2024, then jumped by 96.22% to -$5.3 million in 2025, then tumbled by 172.84% to -$14.5 million in 2026.
• The last three Profit After Tax figures came in at -$14.5 million (Q1 2026), -$5.3 million (Q4 2025), and -$6.4 million (Q3 2025), per Business Quant data.